Of note, CD103 is preferentially expressed by tumor‐infiltrating lymphocytes (TILs), and its expression in tumor tissue in NSCLC and ovarian cancers was associated with a good outcome (Djenidi et al., 2015; Webb et al., 2014). The gene discussed is ITGAE; the disease is neoplasm.